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Abstract In recent years, informed consent has been
suggested as a way to deal with risks posed by engineered
nanomaterials. We argue that while we can learn from
experiences with informed consent in treatment and
research contexts, we should be aware that informed
consent traditionally pertains to certain features of the
relationships between doctors and patients and re-
searchers and research participants, rather than those
between producers and consumers and employers and
employees, which are more prominent in the case of
engineered nanomaterials. To better understand these
differences, we identify three major relational factors that
influence whether valid informed consent is obtainable,
namely dependency, personal proximity, and existence of
shared interests. We show that each type of relationship
offers different opportunities for reflection and therefore
poses distinct challenges for obtaining valid informed
consent. Our analysis offers a systematic understanding
of the possibilities for attaining informed consent in the
context of nanomaterial risks and makes clear that mea-
sures or regulations to improve the obtainment of in-
formed consent should be attuned to the specific inter-
personal relations to which it is supposed to apply.
Keywords Informed consent . Nanomaterial risks .
Relationalautonomy.Roomfor reflection . Interpersonal
relationships
Introduction
The notion of informed consent has major significance
when dealing with the risks associated with medical
treatment and experimentation. The main idea behind
informed consent is that individuals should be able to
make their own knowledgeable and voluntary decisions
concerning their exposure to potential dangers, thereby
emphasizing the importance of individual autonomy
and responsibility for balancing risks and benefits. In
this paper, we discuss the application of informed con-
sent to engineered nanomaterial risks. To do justice to
the different social context in which nanomaterial risks
emerge, we explore how social relations influence the
validity of informed consent.
Toxicologists, risk assessors, and environmental sci-
entists have not yet reached consensus on the alleged
hazardous effects of newly engineered nanoparticles
and nanostructured materials (from now on
Bnanomaterials^1). Innovation in fields such as material
sciences, chemistry, and physics has led to the possibil-
ity to create and manipulate matter on the nanoscale.
This has led to the production of nanomaterials with
economically promising new traits such as a higher
reactivity, different polarity, and increased mobility.
However, the identification and evaluation of these
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1 This paper focuses on nanomaterials that are intentionally pro-
duced as active nano-sizedmaterials.We acknowledge that there is
strong overlap in the toxic properties suchmaterials may havewith
naturally occurring or process generated nanomaterials; therefore,
much of the discussion that follows will be applicable to these
materials as well.
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materials is problematic due to a general lack of knowl-
edge about them and of how they interact with the
environment. Furthermore, limitations in measurement
techniques have made formulating occupational expo-
sure limits difficult [1]. Nevertheless, caution is advised,
especially in the occupational context, due to the poten-
tial risk to human health and safety [2–4].
In response to this uncertainty about hazards, several
authors have suggested that informed consent may be
applied to decisions on the desirability of new
nanomaterials. It has been argued that nanomaterials
are experimental in the sense that the impact of these
risks may become fully clear only after these new ma-
terials have been introduced into society [5, 6]. Al-
though there is much uncertainty about the risks posed
by nanomaterials, they are now regularly introduced
into the environment and society [7, 8]. In that respect,
informed consent may be an interesting model to judge
the acceptability of such social experiments with
nanomaterials. And indeed, proponents of informed
consent in the context of nanomaterials argue that it
would be better to obtain some form of consent from
citizens, allowing them to decide whether they are will-
ing to be exposed to the risks posed by these technolog-
ical products. Shrader-Frechette considered this one of
the primary duties of government in regulating
nanomaterials, arguing that they must B… help citizens
attain their rights to free informed consent to nano-
related risks [9, pp 49].^ Similar suggestions were made
by Jacobs and colleagues [6], who considered the ab-
sence of genuine consent in relation to the risks posed by
nano titanium dioxide to be a topic of ethical concern.
Informed consent is an established principle to deal
with risks in the field of medicine [10–12], but its trans-
lation to the use of nanomaterials is not straightforward.
An objection to the use of informed consent for
nanomaterials may be the uncertainty that accompanies
these materials. Consent cannot be informed if it has no
solid knowledge base, something that seems to be exact-
ly missing in the case of nanomaterials. Without suffi-
cient knowledge about what the risks of nanomaterials
are, it may be hard to balance them against their alleged
benefits and come to valid informed consent. Each med-
ical product will have gone through extensive testing
before it enters the market, whereas risk assessment of
nanomaterials is hardly sufficient to cover all products
developed in this emerging technological field [13].
However, at closer examination, the differences are less
clear. After introduction to the market, many drugs
present unexpected side effects and unanticipated inter-
actions [14], making informed consent in a treatment
context sensitive to uncertainty as well. Participants in
clinical trials are confronted with even more uncertainty
when they decide to be subjected to experimental drugs.
Therefore, uncertainty accompanying nanomaterials is in
our view not a principled reason to refrain from the
implementation of informed consent in the governance
of nanomaterials. Rather, dealing with uncertainty re-
quires an open dialogue about potential side effects and
the limitations of knowledge thereof that is central in
informed consent procedures.
Nevertheless, the context in which informed consent is
traditionally used and developed—namely the medical
field—differs from the context in which most
nanomaterials are used [15]. Drug use and medical re-
search are more highly regulated than the production and
application of nanomaterials that are characterized by
regulatory gaps [16–18]. Additionally, while the need
for medical treatment and the development of new drugs
is often taken for granted, the benefit of nano-enabled
products is less evident [19]. Furthermore, in medical
treatment and research, the application of potentially
hazardous materials is relatively contained; medicines
are administered to individual humans, whereas
nanomaterials may be used in a variety of consumer
products and settings ranging from sports equipment,
building materials, to shoe polish [8, 20]. Unlike individ-
ual risk-taking in medical contexts, exposure to
nanomaterials is more collective in nature which renders
informed consent unsuitable [21]. However, this is not
the case for all exposure to risky nanomaterials. In this
paper, we look at individual market transactions and
workplace exposure to risky nanomaterials both of which
are situations that Hansson identifies as those in which
informed consent could potentially be obtained [21].
Our focus is on one specific difference between the
medical context of treatment and research and the wider
context in which nanomaterials are applied: the relation-
ships between those who produce risks and those who are
exposed to them. We assess how differences in relation-
ships may affect the obtainment of informed consent. We
look at the risks posed by nanomaterials and the main
challenges for achieving informed consent in two settings
in which nanomaterials are handled. Workers are among
the first people to be exposed to new nanomaterials, and
their relationship with their employer influences the vol-
untariness of that exposure. Although a consumer’s deci-
sion to buy a product containing nanomaterials may be
124 Nanoethics (2016) 10:123–138
considered a form of consenting to nanomaterial risk, the
quality of the relationship with the producer—for exam-
ple, whether the relationship is transparent or more dis-
tant—influences the transfer of information about risks.
By exploring the characteristics of the producer–con-
sumer and the employer–employee relationship, and
the opportunities these relationships provide to ob-
tain informed consent as well as the constraints they
place on doing so, we are able to say more about how
informed consent may, or may not, be obtained for
the risks posed by new technologies.
We build on the idea that, in practice, the qualities of
interpersonal and social relationships2 influence the ob-
tainment of valid informed consent. Differences in pow-
er, knowledge, and influence may require a different
interpretation or operationalization of informed consent
in non-traditional contexts. Several authors acknowl-
edge the importance of the relational setting for in-
formed consent [22–26]. A detailed analysis of exactly
which characteristics of relationships influence the ob-
tainment of valid informed consent outside of treatment
or research relationships is, however, lacking. Recog-
nizing the relational influences on informed consent
may assist us either to conclude that informed consent
is not feasible in the context of technological risks or to
adapt the notion of informed consent to certain contex-
tual constraints while maintaining its normative core.
In this paper, we first discuss informed consent in
terms of its various components: competence and volun-
tariness, the transfer and understanding of information,
and the ability to make an individual choice. We then
expand this view by presenting informed consent as func-
tioning in and being the product of a particular relation-
ship. We draw from academic literature to identify which
aspects of relationships (mainly in medical or research
settings) are known to affect informed consent. Based on
these findings, we present amore detailed characterization
of the relationships between producer and consumer and
between employer and employee. We conclude with a
discussion about how best to take such relational aspects
into account when conceiving of informed consent in the
context of the risks posed by nanomaterials.
Informed Consent in Context
The practice of informed consent has its roots in the
medical context. Informed consent refers to the process
of getting permission before a healthcare intervention
can be conducted on a person. It is one of the fundamen-
tal ethical principles in both clinical treatment (medical
ethics) and clinical research (research ethics). Informed
consent functions within a broader regulatory framework
as a legal safeguard to protect the patient’s individual
autonomy [27]. However, this paper focuses on informed
consent as an answer to the moral intuition that many
people share, namely that people have the right to know
what risks they are being subject to and the right to freely
choose which risks they are willing to be subject to and
which ones they do not wish to be subject to.
In medical and research ethics, attempts have been
made to define the elements that constitute informed
consent. Although there are different classifications,
the following elements are generally considered to cap-
ture the basic notion of informed consent: a Bthreshold
component,^ an information component, and a consent
component [28–30]. The threshold component indicates
the preconditions for informed consent, including the
competence of patients and research participants for
independent decision-making and the voluntariness
(i.e., the absence of coercion) of their decisions. The
information component comprises standards for disclo-
sure of information by doctors, as well as patients’
understanding of that information. Discussions
concerning the consent component include the condi-
tions under which a decision can be considered valid.
For example, is a procedurally correct decision suffi-
cient or does it refer to Ban individual’s autonomous
authorization of a medical intervention or of participa-
tion in research?^ [italics in original; 31, pp 78].
These components of informed consent set condi-
tions for reasoning capacities, information transfer, and
control thereby ensuring individual capacity to autono-
mously choose medical procedures or research partici-
pation. However, the literature on the various compo-
nents of informed consent reveals that the ideal case of a
Bpurely autonomous individual^—one who indepen-
dently informs herself and makes an independent deci-
sion based on her own assessment of the desirability of
her exposure to risks—often does not exist in practice.
For Buehler [32], this is a case of Bwishful thinking,^
since patients primarily make medical decisions in close
consultation with their doctors. The professional is also
2 In social scientific literature, the term social relations is often
used to refer to more abstract notions of relationships, e.g., rela-
tions between classes and social groups. Personal relationships are
more direct and often imply informal connections. This paper uses
Brelationship^ to refer to relationships broadly construed, includ-
ing both formal and information and distant and proximate
relationships.
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strongly involved in the information component as she
has to ensure that the patient has received sufficient
information and reached a full understanding to make
an autonomous decision [31]. But also framing effects
or informational manipulation may lead to patients be-
ing influenced by doctors when information is presented
or framed in such a way that the patient is directed
toward a particular choice thereby threatening the pos-
sibility of voluntariness [33, 34]. Such influence is not,
of course, only internal to the doctor–patient relation-
ship. Third parties, social expectations, and pressure
may also pose a threat to the validity of informed con-
sent [35]. For example, expectations about gender roles
have been shown to influence women who consented to
gynecological interventions even though they did not
really agree with the medical procedures [36].
Most, if not all, decisions are not the mere result of
individual reasoning based on individual capacity but
are shaped by a social context consisting of personal,
family, and professional relationships. This observation
has led people to argue that we should conceive of
autonomy not as an individual capacity but as a rela-
tional notion [37], shifting attention to the interpersonal
dynamics that underlie individual decision-making.
Certain kinds of relationships may impede with indi-
viduals’ ability to make independent decisions, whereas
others facilitate and foster voluntary and informed deci-
sion-making. This goes beyond direct interference. Pro-
ponents of this notion of relational autonomy have ar-
gued that even our conception of autonomous choice is
itself shaped by, and is the product of, a specific social
context in which we live. Relationships with parents,
teachers, friends, etc. shape our identity, our capacities,
and our understanding of ourselves as autonomous in-
dividuals [38]. If socialization is oppressive, this may be
detrimental to the ability of people to reflect on their
options. McLeod and Sherwin for example argue that
being members of oppressed groups, such as immigrant
communities, in the long run leads to reduced self-trust
and can undermine group members’ capacities for au-
tonomous choice in medical settings [39].
If we take seriously the claim that social relationships
shape autonomy to a great extent, then we need a concep-
tion of informed consent that is sensitive to the relational
context in which it functions. Therefore, the remainder of
this paper will be a first step in developing a relational
approach to informed consent for nanomaterial risks. We
maintain that the quality of informed consent can be
assessed not only in terms of individual capacity but also
as the product of a specific relationship and the character-
istics of the relationship in which it functions.
A key notion here is reflection: the validity of in-
formed consent depends on the room for individuals to
reflect on the influence of their surroundings and the
quality of that reflection. Christman argues that as long
as a person B… maintains the ability to adequately
reflect on … [her] conditions and embrace them … we
should continue to label her autonomous^ [40, pp. 155].
This means that compliance with a social setting, with
its norms and values, or even obedience to others, can be
considered autonomous as long as an individual makes
this choice after having reflected on it. This, of course,
presupposes that an individual has an actual choice and
the liberty to make that choice [41]. Reflection cannot
compensate for an absence of alternatives. However, we
know that reflection itself is susceptible to socialization.
The focus of our discussion here will not be on what
makes up qualitatively good reflection and what influ-
ence socialization should or should not have; this goes
beyond the scope of this paper. Nonetheless, our discus-
sion will show that several characteristics of relation-
ships can contribute positively to empowering individ-
uals that may have been silenced or rendered powerless.
Indeed, we will develop a more procedural approach
with a focus on the context of decision-making rather
than a substantive approach that would define what
autonomy actually entails and what type of behavior or
thoughts are necessary for autonomous choice. Several
authors have argued for something similar [25, 37] but
not in the context of nanomaterial usage. In the follow-
ing, we expand this procedural relational approach to
informed consent with a view to informing a debate
about the desirability of informed consent for dealing
with nanomaterial risks. The next section discusses a
characterization of relationships in order to examine in
more detail the ways in which relationships affect room
for reflection and thereby the validity of informed con-
sent in consenting to risks.
Informed Consent Decisions in Different Types
of Relationships
A range of relationships may be at play in informed
consent decisions. Here, wemodel these relationships as
an example of a dyadic relationship between a risk-
imposer and a risk-bearer. The basic idea is that one
party (the risk-imposer) introduces a risk that is borne by
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another party (the risk-bearer). At present, informed
consent means that the risk-imposer is allowed to intro-
duce a risk if, and only if, the risk-bearer has given her
informed consent to the introduction of the risk. This is
obviously a simplification of the various relationships
that are at play in informed consent. However, this
approach is helpful in establishing some of the structural
differences between relationships in which informed
consent has already been studied extensively—that is,
those between doctor and patient and between research-
er and research participant—and relationships in which
informed consent is less studied, namely those between
producers and consumers and between employers and
employees and that are relevant to the case of exposure
to nanomaterial risks.
This section proposes a framework for characterizing
the relationship between risk-imposer and risk-bearer
that is based on the literature on doctor–patient and
researcher–research participant relationships. We also
discuss how structural differences between relationships
allow for more or less room for reflection and thereby
influence the validity of informed consent. In the
BDiscussion^ section, we use this framework to charac-
terize the relationships between producers and con-
sumers and between employers and employees.
Ideal-Typical Relationships in Medicine and Research
Settings
Although many authors emphasize the importance of
relationships in arriving at autonomous decisions, they
have largely left the nature of these relationships undis-
cussed. Nevertheless, some typologies have been pro-
posed to capture the structural differences between the
relationships in which informed consent decisions are
made. The ideal types discussed in this section refer to
various forms and dimensions of control between pa-
tients and doctors and investigators and subjects. In
these models, actors exert influence at different levels
and in different ways in relation to different expressions
of autonomy.
Ezekiel and Linda Emanuel offer a well-known ty-
pology that distinguishes four models of the doctor–
patient relationship [42]. The first, the Bpaternalistic^
model, describes a doctor who is considered the pa-
tient’s guardian, treating the patient in a way that is
deemed medically correct, with the patient simply
assenting to the doctor’s decision. In the Binformative^
or Bconsumer^ model, the doctor provides the patient
with all the relevant information and leaves the decision-
making to the patient. This model offers more autonomy
than the paternalistic model as patients are seen as
actively making decisions rather than simply following
the doctor’s advice. There have been objections to this
model, however, because it makes the role of the doctor
too technical and lacks a Bcaring approach^ [43]. This
objection is overcome in the Binterpretive^ model,
where the doctor helps the patient to reflect on her
own values and decide what she wants. In this case,
the doctor acts more as a consultant or therapist.
Emanuel and Emanuel ’s four th model , the
Bdeliberative^ model, is more symmetrical: the doctor
actively discusses treatment with the patient, who uses
the doctor’s expert knowledge but also actively engages
in her own treatment process.
The main distinguishing factor between the ideal
types described by Emanuel and Emanuel seems to be
the level of control over medical decisions (see Table 1).
More paternalistic models leave little room for patient
agency, whereas the interpretive and informative models
emphasize patients’ individual freedom of choice. Even
though some models, such as the informative model,
Table 1 The table summarizes the models of medical treatment
relationships, based on the work of Emanuel and Emanuel [42].
The columns represent different ways of dividing responsibilities
for medical decision-making. Even though some models, such as
the informative model, ascribe a smaller role to doctors in making
the decision, they may still highly influence it by presenting
information in a particular way
Paternalism Informative/consumer Interpretive Deliberative
Who has control over the
information?
Doctor Doctor actively shares all
information with patient
Doctor about medical information,
patient about own values
Both share and exchange
information, although doctor
has medical expertise
Who makes the decision? Doctor Patient chooses; doctor
has to accept patient’s
preferences
Doctor helps patient as
consultant to discover own
preferences and values
Patient and doctor deliberate
together, although the patient
makes the final decision
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ascribe a smaller role to doctors in the actual making of a
decision, they may still be highly influential through the
way they present information. These Bframing effects^
can be very powerful sometimes even creating anxiety
and harming patients [44].
Other ideal types that have been developed in re-
search environments show that differences in the rela-
tionship between researcher and research participant are
multidimensional and potentially asymmetrical in vari-
ous ways. Philosopher Joan Cassel [45] developed a
typology of research relationships to assess the appro-
priateness of ethical principles in those relationships
(Table 2). She distinguished between research relation-
ships in different fields showing how they vary in terms
of the researcher’s power and control over the research
setting and context as well as the direction of the re-
search interaction. Experimental biomedical researchers
have a lot more power and control over their research
participants compared to anthropological field workers
who use such methods as participant observation. In
biomedical experimentation, researchers define the ex-
perimental setting and determine what the participant
should do. This is much less the case in social sciences
research in which the research participants have much
more agency because the research takes place in their
own social settings, and methods of participant obser-
vation require minimal interference by the researcher
(for example [46]. Finally, the direction of interaction
in research is a further important distinguishing factor.
Participants in biomedical, psychological, and survey
research have very limited interaction with the research-
er (they basically provide answers and/or information),
while in anthropological fieldwork, the participants of-
ten actively steer the research and have a much more
equal role in communication. A limitation of this typol-
ogy is that it does not specify what characteristics of
relationships allow for more or less control or more or
less power on both sides.
Relational Factors that Influence Informed Consent
To clarify which characteristics of relationships allow
the risk-bearer to be more autonomous, we need a more
detailed conception of what constitutes these relation-
ships. Therefore, this section presents empirical litera-
ture from bioethics, the social sciences, and law on the
relational characteristics that influence informed consent
practices or similar kinds of decisions. We look at three
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proximity, and (3) shared interests. This information can
provide us with insight into the relationship between
informed consent and the social context of its applica-
tion, in general, as well as deepen our understanding of
which aspects of relationships may be supportive of or
disruptive to relational autonomy.
Dependency
Asymmetry in expertise and knowledge concerning the
risks associated with products and treatments makes risk-
bearers dependent on risk-imposers for disclosure and an
understanding of the information. Risk-imposers and
risk-bearers often do not have the same information
about the risks of an intervention or drug or about
exposure to dangerous substances. According to Faden
and Beauchamp [10], the main obstacle to informed
consent in the medical context is informational manipu-
lation which occurs when information is presented or
framed in such a way that the patient is directed toward a
particular choice [10, 47, 48]. This can be done because
there are often great inequalities in the information avail-
able to patients and doctors—this is known as Binforma-
tional asymmetry^ [22]—with patients often depending
on doctors for access to, and the interpretation of, risk
information. Aside from dependency in the provision of
information, there may also be a difference in the capac-
ity of risk-bearers to understand the information provid-
ed by doctors and researchers [49], for instance due to
illness [50, 51] or simply the patients’ lack of expertise.
Dependencies—such as informational asymmetry
and risk-bearers’ dependency in understanding risk in-
formation—may give rise to situations in which the
obtainment of informed consent is strongly influenced
by the power relation between risk-imposer and risk-
bearer. The existence of power is almost by definition
relational: Power exists only by virtue of there being
somebody to influence or control with that power. In
medical practice, doctors can exert considerable influ-
ence over medical decisions by, for example, imposing
their values. Coercion is not at all uncommon in medical
practice [see for instance, 48, 52–54]. Furthermore,
doctors are important gatekeepers for medical treatment
and medical resources.
Personal Proximity
The ties between the risk-imposer and the risk-bearer
have become increasingly closer in research and
medical practice. According to Miller and Boulton
[55], research relationships in the social sciences have
become much more personal and conversations have
become more dialogical. Researchers sometimes devel-
op what are known as Bfake friendships^ with partici-
pants, immersing themselves in the field through partic-
ipant observation resulting in very open contact.
A similar phenomenon can be seen in the medical
field, where doctors and patients need common ground
to discuss the course of treatment. For example, shared
values are said to be very important in meeting patients’
physical and psychological needs [56]. It may also be
important for doctors to become familiar with their
patients’ frames of reference and values to understand
why their patients turn to alternative treatments that,
medically speaking, may not be the best choice. Addi-
tionally, close bonds also seem to positively influence
information transfer and genuine understanding as a
personal and trusting relationship positively influences
the understanding of medical information [57].
Furthermore, the continuity of therapeutic and re-
search ties may interfere with the validity of consent.
Doctor–patient interactions can be seen as long-term
commitments rather than as one-off decisions to arrive
at a form of consent [22]. These relationships are built
over time: a doctor monitors a patient’s health and may
change the treatment regime as required. Something
similar is seen in sociological and anthropological re-
search. For example, in participant observation, there is
an ongoing interaction between the researcher and the
participant [58]. On the one hand, building strong and
long-term bonds in the field is often inherent in being a
good social researcher. On the other hand, individuals
may feel pressured to make choices that maintain their
relationship with, for example, health professionals thus
threatening the voluntariness of their consent [26].
Therefore, informed consent procedures must
achieve a balance between closeness and distance. In-
formed consent is often presented as an alienating, for-
malized practice that can be very impersonal and highly
bureaucratized. For instance, according to Clarke [59],
many informed consent procedures have become for-
malized decisions that may leave little room for ques-
tions and dialogue. Miller and Boulton [55] also ob-
served a strong standardization of ethical and informed
consent procedures in the social sciences. However, this
does not always need to be an issue. For instance, in
social science research, there is often no clear moment
of initiation or involvement in a study [60]. Especially
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when using participant observation, a research partici-
pant is unlikely to be directly asked for her informed
consent [24]. There seems to be no clearly demarcated
moment for doing so and, in this respect, increasing
formalization may assist the actual obtainment of in-
formed consent. This indicates that maintaining the right
distance is key to making informed consent decisions.
Shared Interests
The relationships in which informed consent decisions
are made differ in the degree to which there is some sort
of shared interest between the risk-imposer and the risk-
bearer. This shared interest is most obvious in the treat-
ment relationship between doctor and patient: Here, the
doctor has a fiduciary duty toward the patient which
means having to act according to the interests of the
patient [22, 61]. Thus, a doctor must not only inform
patients about risks and allow them to make a decision
but also tell them about alternative treatments. This is
not to say that patients’ interests are always entirely
clear: Research has shown that there is strong variation
between patients’ preferences in medical decision-
making [62]. Patients may also form and shape their
preferences during the decision-making process in line
with the interpretative model of Emanuel and Emanuel
[42] in which doctors help patients to discover and order
their values to come to medical decisions. However,
patients or their guardians may misinterpret the inten-
tions of doctors due to the social status of medical
institutions. For example, in academic hospitals, doctors
are often also researchers who have an interest in high
rates of participation in trials [63]. This has conse-
quences for the obtainment of informed consent: Parents
may misinterpret activities that are experimental as be-
ing therapeutic and think that the doctor is only acting in
their child’s best interest. Something similar can be seen
in the social sciences, where researchers often engage
with politically loaded or sensitive topics. In these set-
tings, researchers may be mistakenly perceived as ad-
vocates or activists, whereas their primary loyalty is to
the academic community in providing a theoretically
sound, objective account—though various forms of en-
gaged anthropology seem to merge these two roles [64].
Room for Reflection
As argued in the BInformed consent decisions in differ-
ent types of relationships^ section, relationships
influence the room for reflection that is crucial for
obtaining valid informed consent. The previous section
discussed the characteristics of relationships in which
informed consent decisions are made. Depending on
their characteristics, relationships may offer different
opportunities for reflection. For instance, in a relation-
ship in which there is strong dependency because of
informational asymmetry, risk-bearers have less capac-
ity to genuinely reflect on their options. Strong personal
bonds, on the other hand, may enhance reflection as is
revealed in the deliberative model of the doctor–patient
relationship. The existence of conflicting interests may
prompt reflection as conflict enables us to see differ-
ences in the values that guide risk decisions.
The relational factors identified in the previous section
enable us to evaluate the validity of informed consent
from a relational perspective (see Table 3 for an
overview) not only because these individual factors
themselves influence the reflection of risk-bearers on
the information and decisions with which they are
confronted but also because these factors help the risk-
bearer to reflect on her relationship with the risk-imposer:
One can only be really autonomous by reflecting on the
characteristics of the relationship one is in, and how those
characteristics may influence the decision one makes.
Characterizing Employer–Employee
and Producer–Consumer Relationships
Relationships need to meet certain levels of indepen-
dence, shared interests, and proximity to allow for re-
flection and the obtainment of valid informed consent.
This section explores two relationships that are promi-
nent in decisions concerning nanomaterial risk: the re-
lationship between employer and employee and that
between producer and consumer. We characterize these
relationships in terms of the characteristics introduced in
the previous section, that is, in terms of dependency,
personal proximity, and the existence of shared interests.
Next, we discuss what room for reflection these rela-
tionships offer.
Relational Factors
The characterization we present describes the employ-
er–employee and producer–consumer relationships, in
general, in ideal-typical terms.
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Dependency
The relationship between producers and consumers is
often considered to be one in which the consumer is
fairly independent. In an ideal market, market transac-
tions are, by definition, similar to informed consent
decisions: For a market transaction to be considered
genuine, all decisions have to be made knowingly and
willingly. Producers and consumers are fairly autono-
mous in their decision to partake in a specific market
transaction: they can buy from or sell to whomever they
choose. Nevertheless, in many cases, there may also be
some form of dependency among consumers because, for
example, there are not enough alternatives to make a free
choice, or a producer has a monopoly on certain products
(such as the near monopoly of Microsoft in the 1990s).
In ideal market transactions, both the producer and the
consumer have complete information about the product
and its possible hazards, whichwould suggest we can see it
as a form of informed consent. In practice, of course,
complete information is never available. In many jurisdic-
tions, therefore, the producer has a legal duty to inform
buyers about any known negative effects through labeling
thus making the informational position of consumers
somewhat similar to that of the patient in the doctor–patient
relationship. One difference from the doctor–patient rela-
tionship, however, is that a producer is not expected to
offer consumers information about alternatives that may
better suit their needs—which would obviously be against
the producer’s economic interests. Moreover, there is usu-
ally no personal contact between the risk-imposer
(producer) and the risk-bearer (consumer), unlike in the
doctor–patient relationship. This may make transferring
knowledge of the risk more difficult, with the risk-
imposer unable to verify whether the risk-bearer has really
understood the risk. As a result, informational asymmetry
threatens the risk-bearer’s opportunity to reflect on the
desirability of being exposed to that risk. Also, consumers
often have little or no say in design processes (despite all
the participatory initiatives that have emerged in recent
years), so in this respect, too, they very much depend on
the efforts of producers to make less risky products.
The presence of free choice is much less obvious in
working environments. The hierarchy in working envi-
ronments means the employer is responsible for the
working conditions of her employees: employees depend
greatly on their employers to make the right decisions
concerning exposure to risks, and employers are in many
countries legally responsible for organizing a safe work-
ing environment. The individual choice of employees is
limited, making this type of relationship rather asymmet-
rical in terms of power. It must be noted, though, that the
academic environments in which nanomaterials are used
and produced are typically characterized by more inde-
pendence and self-determination in working practices.
Personal Proximity
The strength of ties in both employer–employee and
producer–consumer relationships may vary consider-
ably depending on the context. In some markets and
for some products, there may be strong and enduring ties
between producers and consumers; in other cases (e.g.,
consumer products that can be bought at a supermarket),
the ties may be much looser: Consumers may be anon-
ymous to producers and a personal bond may be absent.
Employer–employee relationships are, in general, less
anonymous as there is often interaction on a daily basis
Table 3 Relational factors that may influence the autonomy of informed consent or similar decisions
Factor Evaluated in terms of:
Dependency • Dependency on risk-imposer for information
• Understanding dependency due to differences in level of education, knowledge, and cognitive abilities
between risk-bearer and risk-imposer
• Dominance of one actor’s view in decision
• Existence of visible and invisible coercion
Personal proximity • Level of anonymity, intensity if contact, and sharing of personal information
• Relational continuity, duration of the contact (multiple meetings)
• A balance in formalization/informalization of contact (e.g., as a result of standardization and bureaucratization)
Shared interests • Similarity between the interests of the risk-bearer and those of the risk-imposer, as well as the extent to
which one can rely on another to act in one’s interests
• Existence of legal and moral duties of one party to protect the other party’s interest
• Presence of commercial or other conflicting interests
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and these relationships usually last longer than produc-
er–consumer relationships. Again, however, there may
be quite some differences between employees who are
hired on a temporary basis through an employment
agency and those who spend their entire working lives
with the same employer which leads to strong personal
bonds between them.
Whenwe focus on nanomaterials, the following ideal-
typical picture arises. Companies that develop and use
nanomaterials often employ skilled workers who, we
assume, work there for at least a number of years making
the ties between employer and employee stronger and
distances (e.g., in hierarchy) easier to bridge. Although
this may lead to shared interests (see also the following
section), long-term bonds may also pose a risk and lead
to self-sacrificing behavior by employees out of loyalty
to an irresponsible employer or in order to hold on to a
valuable job. Phenomena such as group think—a ten-
dency to prefer harmony within the group over the right
or best outcomes—suggest that stronger social ties may
also diminish the space for reflection [65]. Similarly, we
know that shared decision-making processes may lead to
group polarization [66] where a groups comes to hold
more extreme views than the individual members of the
group held initially.
Market transactions are, in general, much more dis-
tant. As is the case in biomedical research settings,
producers and consumers do not have contact on a
regular basis, and any contact there tends to be relatively
brief and instrumental. Furthermore, market transactions
often go through sellers and re-sellers, leading to large
distances between the risk-producer and the consumers
who are exposed to the risks. This limits the opportunity
for consumers to communicate with producers about the
risks posed by new technological products with the
contact rather unidirectional. This is especially the case
for one-time buyers although some consumers are
loyal to particular brands. The latter may be in a
better position to make informed decisions because
of this stronger connection.
Shared Interests
If we assume that producer–consumer relationships are
guided by the market, then producer and consumer have
a shared interest in the transactions they agree on, but
apart from that, there need not be a shared interest. In
comparison, employer–employee relationships seem to
be characterized by stronger shared interests, as both
have, at least in principle, a shared interest both in the
performance of the company and in some minimally
decent working conditions. Nevertheless, the history of
labor movements suggests that these shared interests
have not always been recognized and acted upon by
the parties involved.
If we focus on nanomaterials, it is particularly inter-
esting to look at the extent to which there is a shared
interest in safety and protection against potential occu-
pational health and safety risks. The extent to which
safety in this field is a shared interest depends not only
on the ideal-typical characteristics of the producer–con-
sumer and the employer–employee relationship but also
on relevant laws and regulations. Relevant to the pro-
ducer–consumer relationship is the fact that under cur-
rent product liability regulation in the EU, there is a
strict liability for risks [67]. It prescribes caution and
requires rigorous testing for products introduced to the
market and holds companies liable for any undesirable
effects of the products (in the case of normal use). For
the employer–employee relationship, it is relevant that
most Western countries have established a legal duty for
employees to guarantee the safety of the work environ-
ment for employers by, for example, implementing risk
management and preventative measures. This means
that, as is the case with product liability, the health and
safety of the risk-bearer (in this case, the employee) are a
concern for both the risk-bearer and the party exposing
that person to a risk (here, the employer). It is a shared
interest according to the law.
However, the extent to which interests overlap is
more encompassing in the case of the employer–em-
ployee relationship. Producers are primarily concerned
with the safety of a specific product while employers are
concerned with the health of personnel in their working
environment. Thus, employers have a duty of care to
their employees and, perhaps not surprisingly, the em-
ployer–employee relationship exhibits similarities to the
more paternalistic doctor–patient relationship. The pro-
ducer–consumer relationship, on the other hand, leaves
muchmore room for personal consideration and is much
more similar to an informative or consumerist relation-
ship model (to use Emanuel and Emanuel’s typology).
In general, we do not expect producers and commercial
players to look beyond the safety of their products in
meeting the needs those products are intended to meet.
This would not be in the commercial interest of compa-
nies and would entail a level of engagement of pro-
ducers with their clients that is rarely seen. Depending
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on the level of shared interest, it is to be expected that
risk-bearer and risk-imposer are more engaged in
supporting the risk-bearer’s decision-making strategy
thereby enabling autonomous reflection.
Room for Reflection
The relationship between employer and employee and
that between producer and consumer vary in terms of
dependency, strength of bonds, and level of shared
interests. Since autonomy is shaped by the characteris-
tics of relationships, the validity of informed consent is
contingent on these characteristics. The discussion in
this section suggests that employer–employee relation-
ships and producer–consumer relationships provide dif-
ferent amounts of room for reflection. In working rela-
tionships, strong bonds with and dependency on the
employer may limit opportunities for critical reflection
and autonomous risk decisions. Conversely, in the pro-
ducer–consumer relationship, room for reflection is par-
ticularly threatened by too loose bonds and the absence
of shared interests. Thus, the framework developed in
the previous section helps us to see that it might be hard
to achieve valid informed consent in producer–consum-
er relationships and in employer–employee relation-
ships albeit it for quite different reasons. This alsomeans
that what we can, and maybe should, do to improve the
obtainment of valid informed consent is quite different
for these different types of relationships.
Discussion
In an ideal world, informed consent is given under
optimal conditions of voluntariness, complete disclo-
sure, and understanding of information. However, in-
formed consent functions within the dynamics of a
particular relationship between a risk-imposer and a
risk-bearer. This relationship should preferably be sym-
metrical in order to decrease the dependency of the risk-
bearer on the risk-imposer. A certain level of personal
contact is needed to ensure proper information disclo-
sure and to create a space for genuine discussion about
the risks and benefits of a particular product in order to
increase understanding. At the same time, the personal
ties should not be so strong that the risk-bearer feels
forced to act in accordance with the risk–imposer’s
proposal without proper reflection—making it effective-
ly a power relation. A strong overlap of the interests of
the risk-imposer and the risk-bearer prevents conflicts of
interests and deception or exploitation but some conflict
of interest, or of values, between risk-imposer and risk-
bearer may be instrumental in prompting reflection.
The world, however, is not perfect. Relationships
between doctor and patient and between researcher
and research participant, as well as those between pro-
ducer and consumer and between employer and em-
ployee, differ in various ways from the ideal-typical
relationship that is presupposed in informed consent.
Dependency seems to be more asymmetrical in medical
treatment and working relationships. The extent to
which shared interests exist varies: doctor–patient rela-
tionships are typically characterized by strong overlap-
ping interests, whereas this is less obviously the case for
the other relationships. Furthermore, the proximity in
these relationships is very different: Market relation-
ships and research relationships (in particular biomedi-
cal relationships) may be rather impersonal and distant,
whereas employees and employers may sometimes
build upon long-term and often personal ties that are
similar to those in treatment relationships. Of course,
this characterization is based on a rather generalized
image of what these relationships look like, and there
may be many variations. There is a certain range, how-
ever, within which these relationships operate (Table 4).
Different relationships pose different challenges
when it comes to room for reflection and achieving valid
informed consent. Much of the literature on informed
consent identifies information dependency in the doc-
tor–patient relationship as one of the major challenges in
achieving informed consent. Our paper also argues that
the close bonds in these relationships may also pose a
risk to the capacity for reflection and autonomous
choices. Highly proximate relationships leave little
room for patient independence and may invoke pater-
nalism. The relationship between employer and employ-
ee appears challenging in a different way. The hierarchy
between them impedes the making of a genuinely vol-
untary decision. While there may be a degree of equality
in the working relationship, the employee always de-
pends on the employer to ensure the safety of the work
environment and the security of her job. It is therefore
unlikely that an employee will be in a completely sym-
metrical relationship with her employer which may
threaten the voluntariness of risk decisions. In research
relationships, and primarily in biomedical research rela-
tionships, the limited overlap in interests also creates
problems for informed consent. There is often no
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immediate need for research participants to be part of a
research project although history shows that deception
has led to participation in research. In social science, the
personal proximity poses more of a challenge.
Finally, the sheer distance between consumer and
producer leads to informed consent being obtained rath-
er indirectly. It is unlikely that producers will develop
very strong ties with their consumers, and as a result, the
risk-imposing producer cannot monitor whether the
consumer has received and genuinely understands the
information provided. Marketing departments could
play a role in this3 but still the consumer can only
consent through a market transaction and this hardly
offers an opportunity to ask for further clarification.
Consequently, different relationships provide different
amounts of room for reflection both on the information
available for making decisions and on the way such
relationships shape the autonomy of the risk-bearer.
Considering the variations in these relationships, we
conclude that informed consent would not function in
the same way in different types of relationships. Institu-
tional changes that may be useful in the doctor–patient
relationship may have a detrimental effect in the em-
ployer–employee relationship and vice versa. In other
words, any implementation of informed consent must
take into account the particularities of the relationship in
which the consent functions. Our systematic analysis is
a first step toward improving the conceptualization of
informed consent in a way that does justice to these
relational differences by providing a more fine-
grained account of the conditions under which valid
informed consent can be obtained. The following
subsection discusses the implications of this for the
feasibility of obtaining informed consent for expo-
sure to nanomaterial risks.
Implications for Informed Consent as a Way to Deal
with Nanomaterial Risks
Informed consent has been proposed as a way to deal
with the risks and benefits that products containing
nanomaterials pose to consumers. These efforts have
typically focused on providing better information to
consumers and on addressing the information asymme-
3 Developments such as the conscious consumerism movement
show that consumers feel increasingly connected to certain brands
on ethical grounds. This allows brands to build relationships with
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try between producers and consumers [cf. 9]. Such
efforts include, for example, the labeling of nano-
content in cosmetics [68], additional product informa-
tion, and the provision of online databases with
voluntary application and risk information from the
manufacturers [8, 20]. Both citizen panels and partici-
patory risk assessment bring citizens’ knowledge level
closer to that of developers [69] and give citizens influ-
ence on future technological developments [70]. NGOs
often play a role in facilitating knowledge transfer, for
instance by increasing the visibility of nanomaterial use
and by encouraging informed public debate.
Although we know from experience with informed
consent in doctor–patient relationships that it is impor-
tant to address asymmetries in information and under-
standing, our analysis suggests that the weak ties be-
tween producers and consumers also present a major
barrier to acquiring valid informed consent in producer–
consumer relationships. These weak ties are a threat to
the correct interpretation and understanding of informa-
tion and may also result in very limited shared interest.
Our findings suggest that if we want to strengthen
informed consent in producer–consumer relationships,
we should also focus on these aspects, rather than just on
overcoming information dependency. This is, to some
extent, already happening. NGOs do not only provide
risk information but can also help establish relation-
ships, for instance by starting a joint inquiry into the
acceptability of risks [71]. Current trends in responsible
innovation and design studies aim to create even closer
ties between consumers and producers throughmeans of
participatory design and user-oriented design [72].
However, most consumer–producer relationships are
still very distant, especially in an international context.
Some argue that current developments in the field of
nanotechnology create even more dependency from the
global south to the global north [73].
When it comes to employer–employee relationships,
we are not aware of attempts to explicitly use informed
consent as a way to deal with nanomaterial risks to
employees. Nevertheless, there are several ways in
which European Occupational Health and Safety regu-
lation promotes informed consent-like decision-making.
For instance, EU Directive 89/391/EEC on the introduc-
tion of measures to encourage improvements in the
safety and health of workers requires the provision of
information, training of workers, and shared forms of
decision-making (e.g., through consultation and partic-
ipation). Something similar is prescribed in Council
Directive 98/24/EC on the Protection against Chemicals
Risks at Work. Such measures empower individual
workers and ensure that information sharing becomes
a mutual interest for both employer and employee.
More informal guidelines that have been developed
to deal with nanoparticles at the workplace emphasize
the need for direct communication between employer
and employee [2, 4, 74]. The rationale behind this is that
the uncertainty concerning nanomaterials risks has
made the application of existing risk management strat-
egies in workplaces particularly tricky. Conventional
workplace exposure scenarios do not apply to nano-
sized materials, and there is an absence of occupational
exposure limits for most nanomaterials [1]. If employers
do not know whether they can take adequate protective
measures against uncertain risks, it seems reasonable to
at least ask employees whether theymind being exposed
to them. Yet, it must be noted that an obstacle is still the
asymmetrical power relation between employers and
employees which is also maintained in most Western
labor laws. Here, labor unions play and have played a
role in decreasing dependency of the employee on the
employer [75, 76]. All in all, it seems that while the
information component is increasingly addressed in em-
ployer–employee relationships, employees are often not
in a formal position to make a decision regarding their
own use of nanomaterials.
Much more research should be done on how the
characteristics of relationships interact and could com-
pensate for each other and facilitate room for reflection.
A potentially more constructive, but speculative, ap-
proach to informed consent would be to see the three
relational aspects we identified as communicating ves-
sels. Mechanisms that point in this direction can already
be observed. For instance, a high degree of dependency
on employer’s decisions concerning the use of
nanomaterials can to a certain extent be compensated
for by a higher level of shared interests as is the case in
labor law. More distant consumer relationships can also
be partially compensated for by providing consumers
with information about nano-content in their products as
this decreases informational dependency. More re-
search is needed to establish how these different
relational factors could and should compensate for
and interact with each other to achieve genuine in-
formed consent for using, working with, and han-
dling products containing nanomaterials. We hope
that our discussion of informed consent provides a
fruitful starting point for such an analysis.
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